Xencor, Inc. (XNCR)
| Market Cap | 2.15B |
| Revenue (ttm) | 124.27M |
| Net Income (ttm) | -63.75M |
| Shares Out | 58.00M |
| EPS (ttm) | -1.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 18 |
| Last Price | $36.94 |
| Previous Close | $37.04 |
| Change ($) | -0.10 |
| Change (%) | -0.27% |
| Day's Open | 36.57 |
| Day's Range | 36.12 - 37.24 |
| Day's Volume | 413,804 |
| 52-Week Range | 29.28 - 58.34 |
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor (XNCR) delivered earnings and revenue surprises of 94.81% and 160.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
On Wednesday, May 05, Xencor (NASDAQ:XNCR) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor Inc (NASDAQ: XNCR) and UCLA Technology Development Group have agreed to develop novel therapeutic antibodies utilizing Xencor's modular suite of XmAb technology platforms. Xencor's XmAb platform...
MONROVIA, Calif. & LOS ANGELES--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of can...
Xencor (XNCR) delivered earnings and revenue surprises of 55.56% and 97.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.
MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, ...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...
MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INC...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...
Xencor Inc (XNCR) CEO Bassil Dahiyat on Q3 2020 Results - Earnings Call Transcript
Xencor (XNCR) delivered earnings and revenue surprises of 0.00% and -2.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, ...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease,...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases,...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc.
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc.
MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)--Xencor, Inc.
Xencor Inc (XNCR) CEO Bassil Dahiyat on Q2 2020 Results - Earnings Call Transcript
Xencor (XNCR) delivered earnings and revenue surprises of -8.93% and 43.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc.
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc.
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc.
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These hidden gems have the potential to deliver significant returns to their shareholders over the long run.
MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of ...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases...
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2020 Results - Earnings Call Transcript
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2019 - Earnings Call Transcript
Xencor (XNCR) delivered earnings and revenue surprises of 9.62% and -47.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About XNCR
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a... [Read more...]
| Industry Biotechnology | IPO Date Dec 3, 2013 |
| CEO Bassil Dahiyat | Employees 202 |
| Stock Exchange NASDAQ | Ticker Symbol XNCR |
Analyst Forecasts
According to 12 analysts, the average rating for Xencor stock is "Buy." The 12-month stock price forecast is 54.00, which is an increase of 46.18% from the latest price.